Comparative In Vitro Activity of Linezolid and Five Other Antimicrobials Against Nosocomial Isolates of Methicillin-Resistant Staphylococcus aureus, Methicillin-Resistant Staphylococcus epidermidis and Vancomycin-Resistant Enterococcus faecium

Journal of Chemotherapy

Volumn 15, Issue 5, 2003, Pages 442-448

  Metallidis, S ^a   Chatzidimitriou, M ^a   Nikolaidis, P ^a   Tsona, A ^a   Bisiklis, A ^a   Kollaras, P ^a   Tsiakiri, E ^a   Koumentaki, E ^a   Alexiou Daniel, S T ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Enterococcus faecium; Linezolid; Methicillin resistant staphylococci; Oxazolidinones; Staphylococcus aureus; Staphylococcus epidermidis; Vancomycin resistant enterococci

Indexed keywords

CLINDAMYCIN; GENTAMICIN; LINEZOLID; OXACILLIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; ENTEROCOCCUS FAECIUM; HOSPITAL INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; STAPHYLOCOCCUS EPIDERMIDIS; STRAIN DIFFERENCE;

EID: 0142154954     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.5.442     Document Type: Article

References (31)

1. Levy S. Multidrug resistance-a sign of the times. N Engl J Med 1998; 338: 1376-8.
2. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993; 6: 428-42.
3. Marshall SA, Wilke WW, Pfaller MA, Jones RN. Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mecA) characterization of oxacillin resistance in the SCOPE program. Diagn Microbiol Infect Dis 1998; 30: 205-14.
4. Hussain Z, Stoakes L, Massey V, Diagre D, Fitzgerald V, Elsayed S et al. Correlation of oxacillin MIC with mecA gene carriage in coagulase-negative staphylococci. J Clin Microbiol 2000; 38, 752-4.
5. Leclercq R, Derlot E, Duval J, Courvalin P. Plasma-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium. N Engl J Med 1988; 319: 157-61.
6. Baquero F. Gram-positive resistance: Challenge for the development of new antibiotics. J Antimicrob Chemother 1997; 39(Suppl. A): 1-6.
7. Nikolaidis P, Metallidis S, Katikaridou E, et al. Comparative in vitro activity of quinupristin/dalfopristin and seven other antimicrobials against methicillin susceptible and methicillin resistant nosocomial Staphylococcus aureus blood-stream isolates. J Chemother 2002; 14, 6: 544-6.
8. Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-5.
9. Diekema DJ, Jones RN. Oxazolidinones: a review. Drugs 2000; 59: 7-16.
10. Rybak MJ, Hershberger E, Moldovan T, Grucz RG. In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-6.
11. Jorgensen JH, McElmeel ML, Trippy CW. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species. Antimicrob Agents Chemother 1997; 41: 465-7.
12. Munckhof WJ, Harper J, Schooneveldt J, Nimmo GR. Recent appearance of clindamycin resistance in community-acquired methicillin-resistant Staphylococcus aureus (MRSA) in south-east Queensland. Med J Aust 2002; 176 (5): 243-4.
13. Talon D, Deliere E, Bertrand X. Characterization of methicillin- resistant Staphylococcus aureus strains susceptible to tobramycin. Int J Antimicrob Agents 2002; 20 (3): 174-9.
14. Van Griethuysen A, Pouw M, van Leeuwen N, Heck M, Willemse P, Buiting A, et al. Rapid slide agglutination test for detection of methicillin-resistance in Staphylococcus aureus. J Clin Microbiol 1999; 37: 2789-92.
15. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests: Approved Standard M2-A7. NCCLS, Wayne, PA, USA, 2000.
16. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing - Twelfth Informational Supplement: M100-S12. NCCLS, Wayne, PA, USA, 2002.
17. Panlilio AL, Culver DH, Gaynes RP. Methicillin-resistant Staphylococcus aureus in USA hospitals, 1975-/1991. Infect Control Hosp Epidemiol, 1992; 13: 582-/6.
18. Pfaller MA, Jones RN, Doern GV, Kugler K. Bacterial pathogens isolated from patients with bloodstream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42: 1762-70.
19. The SENTRY participants group, Diekema DJ, Pfaller MA, Schmitz FJ, Smayevski J, Bell J, Jones RN, Beach M. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial susceptibility program, 1997-1999. Clin Infect Dis 2001; 32 (Suppl. 2): S114-32.
20. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997; 40: 135-/6.
21. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of Staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998; 36: 1020-7.
22. Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med 1996; 100: 3S-12S.
23. Pfaller MA, Jones RN, Doern GV, et al. Survey of bloodstream infections attributable to Grampositive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. Diagn Microbiol Infect Dis 1999; 33: 283-97.
24. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know. Clin Infect Dis 2001; 32: 108-15.
25. Morbidity and Mortality Weekly Report. Staphylococcus aureus resistant to vancomycin-United States. MMWR 2002; 51: 565-7.
26. Peter Linden, MD. Antimicrobial therapy use of linezolid for gram-positive infections. Infect Med 2002; 19 (1): 25-32.
27. Gonzales RD, Schreckenberger PC, Graham MB. Kelkar S, DenBesten K, Quinn JP. Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179.
28. Tsiodras S, Gold HS, Sakoulas G, Eliopoulos GM, Wennersten C, Venkataraman L et al. Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 353: 207-8.
29. Livermore DM, Mushtaq S, Warner M. Susceptibility testing with linezolid by different methods in relation to published general breakpoints. J Antimicrob Chemother 2001; 48: 445-58.
30. Slatter JG, Stalker DJ, Feenstra KL, Welshman IR, Bruss JB, Sams JP, et al. Pharmacokinetics, metabolism and excretion of linezolid following an oral dose of [14C] linezolid to healthy human subjects. Drug Metabol Dispos 2001; 29:1136-45.
31. Tenover FC, Biddle JW, Lancaster MV. Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus. Emerging Infect Dis 2001; 7: 327-32.